This study utilized transcriptomic data from The Cancer Genome Atlas (TCGA) to assess SHROOM2 expression across various cancers, investigating its correlations with prognosis, clinicopathological features, TMB, and immune characteristics in pan-cancer, with a specific focus on BC. This evidence concerns the gene SHROOM2 and cancer.